As of 2025-10-31, the Relative Valuation of GT Biopharma Inc (GTBP) is (58.36) USD. This relative valuation is based on P/E multiples. With the latest stock price at 0.63 USD, the upside of GT Biopharma Inc based on Relative Valuation is -9394.5%.
The range of the Relative Valuation is (55.34) - (66.23) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 16.9x - 20.2x | 17.8x |
| Forward P/E multiples | 16.8x - 23.4x | 17.8x |
| Fair Price | (55.34) - (66.23) | (58.36) |
| Upside | -8914.1% - -10647.7% | -9394.5% |
| Date | P/E |
| 2025-10-30 | -0.19 |
| 2025-10-29 | -0.18 |
| 2025-10-28 | -0.20 |
| 2025-10-27 | -0.21 |
| 2025-10-24 | -0.21 |
| 2025-10-23 | -0.22 |
| 2025-10-22 | -0.20 |
| 2025-10-21 | -0.21 |
| 2025-10-20 | -0.22 |
| 2025-10-17 | -0.21 |
| 2025-10-16 | -0.21 |
| 2025-10-15 | -0.22 |
| 2025-10-14 | -0.22 |
| 2025-10-13 | -0.22 |
| 2025-10-10 | -0.21 |
| 2025-10-09 | -0.23 |
| 2025-10-08 | -0.33 |
| 2025-10-07 | -0.23 |
| 2025-10-06 | -0.22 |
| 2025-10-03 | -0.19 |
| 2025-10-02 | -0.19 |
| 2025-10-01 | -0.20 |
| 2025-09-30 | -0.18 |
| 2025-09-29 | -0.18 |
| 2025-09-26 | -0.23 |
| 2025-09-25 | -0.23 |
| 2025-09-24 | -0.24 |
| 2025-09-23 | -0.25 |
| 2025-09-22 | -0.24 |
| 2025-09-19 | -0.24 |
| 2025-09-18 | -0.25 |
| 2025-09-17 | -0.24 |
| 2025-09-16 | -0.25 |
| 2025-09-15 | -0.24 |
| 2025-09-12 | -0.25 |
| 2025-09-11 | -0.23 |
| 2025-09-10 | -0.24 |
| 2025-09-09 | -0.23 |
| 2025-09-08 | -0.26 |
| 2025-09-05 | -0.29 |
| 2025-09-04 | -0.28 |
| 2025-09-03 | -0.29 |
| 2025-09-02 | -0.27 |
| 2025-08-29 | -0.29 |
| 2025-08-28 | -0.30 |
| 2025-08-27 | -0.35 |
| 2025-08-26 | -0.35 |
| 2025-08-25 | -0.33 |
| 2025-08-22 | -0.34 |
| 2025-08-21 | -0.33 |